S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
S&P 500   3,961.70 (-0.05%)
DOW   33,712.24 (-0.20%)
QQQ   284.19 (+0.12%)
AAPL   144.29 (+1.15%)
MSFT   247.03 (-0.15%)
META   116.77 (+1.25%)
GOOGL   93.67 (-0.04%)
AMZN   89.36 (-1.10%)
TSLA   179.98 (+3.77%)
NVDA   172.71 (+0.59%)
NIO   12.85 (-4.18%)
BABA   92.15 (-2.15%)
AMD   69.57 (-1.28%)
T   19.21 (+0.47%)
MU   55.49 (+0.53%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.27 (-1.63%)
DIS   93.94 (+1.50%)
AMC   5.86 (-3.46%)
PYPL   74.18 (-0.05%)
PFE   51.91 (+0.25%)
NFLX   325.29 (+4.84%)
NASDAQ:KRYS

Krystal Biotech - KRYS Stock Forecast, Price & News

$71.63
-2.77 (-3.72%)
(As of 12/9/2022 01:37 PM ET)
Add
Compare
Today's Range
$71.28
▼
$73.50
50-Day Range
$63.14
▼
$78.88
52-Week Range
$47.67
▼
$85.11
Volume
1,001 shs
Average Volume
126,446 shs
Market Capitalization
$1.84 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$107.40

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
49.9% Upside
$107.40 Price Target
Short Interest
Bearish
6.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
-0.39mentions of Krystal Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$143,521 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.36) to ($5.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

346th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

56th out of 171 stocks

See Top Rated MarketRank™ Stocks Here
KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

December 6, 2022 | finance.yahoo.com
2 Risky Stocks That Could Soar in 2023
December 5, 2022 | finance.yahoo.com
Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
December 1, 2022 | finance.yahoo.com
Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
November 23, 2022 | finance.yahoo.com
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
November 17, 2022 | msn.com
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
November 17, 2022 | finance.yahoo.com
Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
November 13, 2022 | seekingalpha.com
Vertex: High Growth For Years Ahead
November 7, 2022 | thestreet.com
Krystal Biotech Needs to Feed the Goldfish in 2023
November 7, 2022 | finanznachrichten.de
Krystal Biotech, Inc.: Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
November 7, 2022 | msn.com
Recap: Krystal Biotech Q3 Earnings
November 7, 2022 | finance.yahoo.com
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
October 15, 2022 | forbes.com
Krystal Biotech
October 12, 2022 | nasdaq.com
Krystal Biotech (KRYS) Shares Cross Above 200 DMA
September 29, 2022 | finance.yahoo.com
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 29, 2022 | finance.yahoo.com
Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 21, 2022 | finance.yahoo.com
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
September 19, 2022 | finance.yahoo.com
2 Growth Stocks That Could Double in the Next Year
September 14, 2022 | finance.yahoo.com
We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
September 14, 2022 | nasdaq.com
A Krystal Biotech, Inc. (NASDAQ:KRYS) insider lowered their holding by 27% earlier this year
September 13, 2022 | bizjournals.com
Krystal Biotech talks the company's strategy, pipeline as it awaits word from FDA
September 10, 2022 | finance.yahoo.com
Krystal Biotech, Inc. (KRYS)
September 8, 2022 | finance.yahoo.com
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 8, 2022 | finance.yahoo.com
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 20, 2022 | tmcnet.com
FDA Accepts Krystal Biotech's Biologics License Application for Dystrophic Epidermolysis Bullosa
August 19, 2022 | finance.yahoo.com
FDA reviewing Krystal Biotech's biologics application
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
11/07/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
CUSIP
N/A
CIK
1711279
Web
www.krystalbio.com
Phone
(412) 586-5830
Fax
N/A
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$107.40
High Stock Price Forecast
$133.00
Low Stock Price Forecast
$74.00
Forecasted Upside/Downside
+49.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,570,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-18.68%
Return on Assets
-17.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.18
Quick Ratio
14.18

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$26.69 per share
Price / Book
2.68

Miscellaneous

Outstanding Shares
25,750,000
Free Float
21,165,000
Market Cap
$1.84 billion
Optionable
Not Optionable
Beta
0.85

Key Executives

  • Mr. Krish S. Krishnan M.B.A. (Age 57)
    M.S., Founder, Chairman, Pres & CEO
    Comp: $1.01M
  • Ms. Suma M. KrishnanMs. Suma M. Krishnan (Age 57)
    Founder, COO, Pres of R&D and Director
    Comp: $708.56k
  • Ms. Kathryn A. Romano (Age 41)
    Exec. VP & Chief Accounting Officer
    Comp: $452.43k
  • Dr. Andreas C. Orth (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $549.17k
  • Ms. Gloria Lin
    Accounting Mang.
  • Mr. Ram Kamineni
    Sr. VP of CMC & Technical Operations
  • Ms. Meg Dodge
    VP of Investor Relations & Corp. Communications
  • Mr. David Glynn
    Gen. Counsel, Commercial & Compliance
  • Mr. John Karakkal
    VP of North American Sales & Marketing
  • Ms. Katherine Tuminello
    HR & Office Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

4 analysts have issued 1 year target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $74.00 to $133.00. On average, they predict the company's stock price to reach $107.40 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2022?

Krystal Biotech's stock was trading at $69.95 at the beginning of 2022. Since then, KRYS shares have increased by 6.4% and is now trading at $74.40.
View the best growth stocks for 2022 here.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our KRYS earnings forecast.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, November, 7th. The company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.06.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.08%), Point72 Asset Management L.P. (4.89%), Lord Abbett & CO. LLC (4.71%), Vanguard Group Inc. (4.26%), State Street Corp (3.86%) and Pictet Asset Management SA (2.81%). Insiders that own company stock include Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $74.40.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $1.92 billion. The company earns $-69,570,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 119 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 12/9/2022 by MarketBeat.com Staff